Skip to main content
Signal8

PSYENCE BIOMEDICAL LTD. (PBM)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Psyence Biomedical Ltd. logo

Psyence Biomedical Ltd.

NASDAQ:PBMHealthcare
AH+0.56%$3.04
Close$3.02+2.03%
Mkt Cap$11.52M
Float2.66M
O/S3.81M
VOL32K sh
$ Vol$96K
RVOL0.62×
Inst Own13.2%
SI0.8%
Dilution
Psyence Biomedical Ltd. logoNASDAQ:PBMAH$3.04+0.56%
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 20262.943.152.943.0231,567
Nov 6, 20263.023.142.952.9624,525
Nov 5, 20263.193.192.852.9433,847
Nov 4, 20263.443.443.103.1818,983
Nov 3, 20263.183.503.113.2954,985
Nov 2, 20263.363.553.163.18116,087
Oct 30, 20263.513.643.283.3146,638
Oct 29, 20263.403.983.403.6162,135
Oct 28, 20263.003.442.983.4032,947
Oct 27, 20263.753.872.703.01244,845
Oct 26, 20264.114.183.633.6646,132
Oct 23, 20264.114.294.064.1713,184
Oct 22, 20264.394.774.124.1257,048
Oct 21, 20264.364.724.364.5239,286
Oct 20, 20264.094.514.064.2444,472
Oct 19, 20264.094.284.084.1234,533
Oct 16, 20264.344.534.164.2226,537
Oct 15, 20264.094.444.094.3216,948
Oct 14, 20264.534.824.104.1368,406
Oct 13, 20264.704.794.554.5535,879
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
13.2%
Institutional
(27)
0.0%
Insiderⓘ
(0)
77.6%
5%+ Owners
(5)
9.2%
Unattributed (incl. retail)ⓘ
Institutional13.2%
5%+ Beneficial77.6%
Unattributed (incl. retail)9.2%
Top Shareholders
NameShares%
Psyence Labs Ltd. logo
Psyence Labs Ltd.
· may incl. warrants· filed Oct 2026
2.6M69.3%
Harraden Circle Investments, LLC logo
Harraden Circle Investments, LLC
PBMWW
1.1M--
Polar Asset Management Partners Inc. logo
Polar Asset Management Partners Inc.
PBMWW
733.0K--
MMCAP International Inc. SPC logo
MMCAP International Inc. SPC
PBMWW
600.0K--
TORONTO DOMINION BANK logo
TORONTO DOMINION BANK
PBMWW
503.0K--
Calamos Advisors LLC logo
Calamos Advisors LLC
PBMWW
500.0K--
Saba Capital Management, L.P. logo
Saba Capital Management, L.P.
PBMWW
297.8K--
AdvisorShares Investments LLC logo
AdvisorShares Investments LLC
258.5K6.8%
AdvisorShares Trust logo
AdvisorShares Trust
· also on 13F· may incl. warrants· filed Oct 2026
258.5K6.8%
Clear Street Group Inc. logo
Clear Street Group Inc.
PBMWW
257.2K--
Sources: 13F, 13D/13GO/S: 3.8M · checked 9 Nov 2026 · market-data provider
Insiders & Institutional Holders

Top institutional holders

About

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines.

It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.

The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care.

It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer.

The company has a strategic collaboration with PsyLabs to produce Ibogaine.

The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Key Metrics
Market Cap$11.52M
Enterprise Value--
P/E Ratio-0.01
Est. Net Cash/Share--
Institutional Ownership13.24%

based on 3.81M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryCACA
IPO DateDec 10, 2021
Shares Outstanding3.81M
Authorized Shares
Float2.66M
52-Week Range
$1.92$18.62
$3.02(7th percentile)
Volume
Average Daily Volume50.64K
31.57K today vs 50.64K avg(-38%)

30d Avg

50.64K

60d Avg

72.70K

90d Avg

78.16K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...